Your browser doesn't support javascript.
loading
Interventions for infantile haemangiomas of the skin: abridged Cochrane systematic review and GRADE assessments.
Novoa, M; Baselga, E; Beltran, S; Giraldo, L; Shahbaz, A; Pardo-Hernandez, H; Arevalo-Rodriguez, I.
Afiliación
  • Novoa M; Paediatric Dermatology Department, Hospital San Jose-Fundacion Universitaria de Ciencias de la Salud, Bogota, Colombia.
  • Baselga E; Paediatric Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Beltran S; Paediatric Dermatology Department, Hospital San Jose-Fundacion Universitaria de Ciencias de la Salud, Bogota, Colombia.
  • Giraldo L; Paediatric Dermatology Department, Hospital San Jose-Fundacion Universitaria de Ciencias de la Salud, Bogota, Colombia.
  • Shahbaz A; Department of Dermatology, University of Alberta, Edmonton, Canada.
  • Pardo-Hernandez H; Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
  • Arevalo-Rodriguez I; Cochrane Ecuador, Centro de Investigación en Salud Pública y Epidemiología Clínica (CISPEC), Facultad de Ciencias de la Salud Eugenio Espejo, Universidad Tecnológica Equinoccial, Quito, Ecuador.
Br J Dermatol ; 180(3): 527-533, 2019 03.
Article en En | MEDLINE | ID: mdl-30414269
ABSTRACT

BACKGROUND:

Infantile haemangiomas (IH) are soft swellings of the skin that occur in 3-10% of infants. When haemangiomas occur in high-risk areas or when complications develop, active intervention is necessary.

OBJECTIVE:

To update a Cochrane Review assessing the interventions for the management of IH in children.

METHODS:

We searched for randomized controlled trials in CENTRAL, MEDLINE, Embase, LILACS, AMED, PsycINFO, CINAHL and six trials registers up to February 2017. We included 28 trials (1728 participants) assessing 12 interventions.

RESULTS:

We downgraded evidence from high to moderate/low for issues related to risk of bias and imprecision. Oral propranolol (3 mg kg-1 daily) probably improves clinician-assessed clearance vs placebo [risk ratio (RR) 16·61, 95% confidence interval (CI) 4·22-65·34; moderate quality of evidence (QoE)]; we found no evidence of a difference in terms of serious adverse events (RR 1·05, 95% CI 0·33-3·39; low QoE). We found the chance of reduction of redness may be improved with topical timolol maleate (0·5% gel applied twice daily) when compared with placebo (RR 8·11, 95% CI 1·09-60·09; low QoE). We found no instances of bradycardia or hypotension for this comparison.

CONCLUSIONS:

Our key results indicate that oral propranolol and topical timolol maleate are more beneficial than placebo in terms of clearance or other measures of resolution, or both, without an increase in harm.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Propranolol / Neoplasias Cutáneas / Timolol / Antagonistas Adrenérgicos beta / Hemangioma Tipo de estudio: Clinical_trials / Systematic_reviews Límite: Humans Idioma: En Revista: Br J Dermatol Año: 2019 Tipo del documento: Article País de afiliación: Colombia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Propranolol / Neoplasias Cutáneas / Timolol / Antagonistas Adrenérgicos beta / Hemangioma Tipo de estudio: Clinical_trials / Systematic_reviews Límite: Humans Idioma: En Revista: Br J Dermatol Año: 2019 Tipo del documento: Article País de afiliación: Colombia